search
Back to results

Acupuncture Versus Sham Acupuncture or Usual Care for Antiandrogen-Induced Hot fLashes in Prostate Cancer (AVAIL) (AVAIL)

Primary Purpose

Hot Flashes, Prostate Cancer, Acupuncture

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Acupuncture
Sham Acupuncture
Sponsored by
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Hot Flashes focused on measuring Prostate Cancer, Hot Flashes, Acupuncture, Randomized Controlled Trial

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • patients aging from 18 to 75 years diagnosed with prostate cancer undergoing ADT;
  • with an average of 3 or more hot flashes a day for at least 3 days before enrollment and no other clinically significant disease;
  • not receiving any medications for hot flashes nor did they have a previous history of acupuncture treatment.

Exclusion Criteria:

  • hormonal treatment other than GnRH analogue
  • daily treatment with psychotropic drugs
  • newly started or changed alternative medications with possible effects on flushes uncontrolled hypertension or metabolic disease
  • inability to move/lie on the side, and treatment with anticoagulants or pacemaker.

Sites / Locations

  • West China HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Sham Comparator

No Intervention

Arm Label

Acupuncture

Sham Acupuncture

Usual Care

Arm Description

Licensed acupuncturists with more than 5 years of experience will be responsible for administering interventions three times per week for 6 weeks. The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling. Acupuncture was defined as targeting the 10 bilateral acupuncture points: Xinshu (BL15), Shenshu (BL23), Zhongliao (BL33), Sanyinjiao (SP6), Yinlingquan (SP9). The needle will be left in place for 30 minutes with brief manipulation at the beginning, middle, and end of therapy.

Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.

Patients receiving usual care received neither acupuncture nor sham acupuncture. After the 6-week assessment, patients will be offered the option to receive acupuncture treatment as the acupuncture group.

Outcomes

Primary Outcome Measures

Weekly mean hot flash symptom severity score (HFSSS)
The HFSSS is defined as the product of "hot frequency" and "hot severity". The severity of hot flashes is assessed based on the duration of hot flashes and physical and emotional symptoms; it is scored as mild, moderate, severe, and very severe (range 1-4, from mild to very severe).

Secondary Outcome Measures

Weekly mean hot flash symptom severity score (HFSSS)
The HFSSS is defined as the product of "hot frequency" and "hot severity". The severity of hot flashes is assessed based on the duration of hot flashes and physical and emotional symptoms; it is scored as mild, moderate, severe, and very severe (range 1-4, from mild to very severe).
Response rate of HFSSS
The responders will be defined according to a 50% reduction of HFSSS
Functional Assessment of Cancer Therapy-Prostate (FACT-P)
The Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire is a relevant, worldwide tool used for assessing the health-related quality of life in men with prostate cancer.
EQ-5D-three-level version (EQ-5D-3L)
The EQ-5D-3L descriptive system comprises the following five dimensions, each describing a different aspect of health: MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION. Each dimension has three levels: no problems, some problems, extreme problems (labelled 1-3). The respondent is asked to indicate his / her health state by checking the box against the most appropriate statement in each of the five dimensions.
International Index of Erectile Function (IIEF-5)
The IIEF-15 comprises 15 items divided into 5 domains: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction, respectively. The IIEF-5 comprises 5 items from the IIEF-15, 4 from the erectile function domain, and 1 from intercourse satisfaction. Response options for each item ranged from 1 to 5, and occasionally the option "0" depicting no sexual stimulation/intercourse, the scores are summed.

Full Information

First Posted
September 26, 2021
Last Updated
June 30, 2022
Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Collaborators
West China Hospital, Yantai Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Jiangsu Cancer Institute & Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05069467
Brief Title
Acupuncture Versus Sham Acupuncture or Usual Care for Antiandrogen-Induced Hot fLashes in Prostate Cancer (AVAIL)
Acronym
AVAIL
Official Title
Acupuncture Versus Sham Acupuncture or Usual Care for Antiandrogen-Induced Hot fLashes in Prostate Cancer (AVAIL): a Multicenter Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2022 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Collaborators
West China Hospital, Yantai Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Jiangsu Cancer Institute & Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Hot flashes are a common and debilitating symptom among prostate cancer patients undergoing androgen deprivation therapy (ADT). Strong evidence from multiple rigorously designed studies indicated that venlafaxine provides partial relief, but the tolerability is poor when the dose is not tapered. Hence, an alternative therapy is needed. Previous studies reported that acupuncture may be helpful in the management of hot flashes. However, the insufficient randomized controlled trial limited the quality of evidence.
Detailed Description
The number of men surviving after being diagnosed with prostate cancer has increased rapidly. According to population-based cancer registry data, 10-year survival has tripled in the past 40 years in the UK. Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment and has been shown in randomized controlled trials to improve overall survival when used with radiation for intermediate- and high-risk localized disease, as well as locally advanced and node-positive disease, and after surgery for the node-positive disease. Although ADT can improve survival, it can also cause significant morbidity and a decrement in quality of life. One of the most bothersome side effects is hot flashes. They are experienced as sudden and transient episodes of heat and sweating, with possible co-occurring palpitations and anxiety, usually persist long-term. The prevalence estimated that 44-80% of patients undergoing ADT report hot flashes and up to 27% report this as the most troublesome adverse effect. Although hot flashes are not fatal morbidity, it may interfere with adherence to lifesaving therapies or ablative therapies that are used to prevent or treat cancer. Currently, most intervention studies for hot flashes have evaluated treatments in breast cancer patients or women who are postmenopausal. Venlafaxine, a selective serotonin reuptake inhibitor, appears to be effective and safe in both breast cancer women and prostate cancer men with hot flashes. It has been recommended for practice in men with strong evidence from multiple rigorously designed studies. However, some prostate cancer patients cannot take venlafaxine because of side effects such as nausea, headache, dry mouth, dizziness, insomnia, and constipation. Thus, an alternative therapy is needed. A systematic review identified six studies of acupuncture for hot flashes, of which none were randomized and placebo-controlled. Although acupuncture is a nonpharmacologic therapy and has been confirmed that could be helpful in the management of hot flashes among breast cancer survivors, there is no placebo acupuncture-controlled trials demonstrating its efficacy in men.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hot Flashes, Prostate Cancer, Acupuncture
Keywords
Prostate Cancer, Hot Flashes, Acupuncture, Randomized Controlled Trial

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomly 2:1:1 allocated to the true acupuncture (n=120), sham acupuncture (n=60), or usual care (n=60) group.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Acupuncture
Arm Type
Experimental
Arm Description
Licensed acupuncturists with more than 5 years of experience will be responsible for administering interventions three times per week for 6 weeks. The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling. Acupuncture was defined as targeting the 10 bilateral acupuncture points: Xinshu (BL15), Shenshu (BL23), Zhongliao (BL33), Sanyinjiao (SP6), Yinlingquan (SP9). The needle will be left in place for 30 minutes with brief manipulation at the beginning, middle, and end of therapy.
Arm Title
Sham Acupuncture
Arm Type
Sham Comparator
Arm Description
Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
Arm Title
Usual Care
Arm Type
No Intervention
Arm Description
Patients receiving usual care received neither acupuncture nor sham acupuncture. After the 6-week assessment, patients will be offered the option to receive acupuncture treatment as the acupuncture group.
Intervention Type
Device
Intervention Name(s)
Acupuncture
Intervention Description
For the active acupuncture group, the acupuncturist chose standard points depending on subjects' preferred positions. In addition, up to four acupuncture points were chosen on the basis of subjects' other presenting symptoms (such as fatigue, insomnia, or erectile dysfunction). The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling.
Intervention Type
Device
Intervention Name(s)
Sham Acupuncture
Other Intervention Name(s)
Placebo Needle, Non-penetrating Acupuncture
Intervention Description
Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
Primary Outcome Measure Information:
Title
Weekly mean hot flash symptom severity score (HFSSS)
Description
The HFSSS is defined as the product of "hot frequency" and "hot severity". The severity of hot flashes is assessed based on the duration of hot flashes and physical and emotional symptoms; it is scored as mild, moderate, severe, and very severe (range 1-4, from mild to very severe).
Time Frame
Baseline to week 6
Secondary Outcome Measure Information:
Title
Weekly mean hot flash symptom severity score (HFSSS)
Description
The HFSSS is defined as the product of "hot frequency" and "hot severity". The severity of hot flashes is assessed based on the duration of hot flashes and physical and emotional symptoms; it is scored as mild, moderate, severe, and very severe (range 1-4, from mild to very severe).
Time Frame
Baseline to week 14
Title
Response rate of HFSSS
Description
The responders will be defined according to a 50% reduction of HFSSS
Time Frame
Baseline, week 6, and week 14
Title
Functional Assessment of Cancer Therapy-Prostate (FACT-P)
Description
The Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire is a relevant, worldwide tool used for assessing the health-related quality of life in men with prostate cancer.
Time Frame
Baseline, week 6, and week 14
Title
EQ-5D-three-level version (EQ-5D-3L)
Description
The EQ-5D-3L descriptive system comprises the following five dimensions, each describing a different aspect of health: MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION. Each dimension has three levels: no problems, some problems, extreme problems (labelled 1-3). The respondent is asked to indicate his / her health state by checking the box against the most appropriate statement in each of the five dimensions.
Time Frame
Baseline, week 6, and week 14
Title
International Index of Erectile Function (IIEF-5)
Description
The IIEF-15 comprises 15 items divided into 5 domains: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction, respectively. The IIEF-5 comprises 5 items from the IIEF-15, 4 from the erectile function domain, and 1 from intercourse satisfaction. Response options for each item ranged from 1 to 5, and occasionally the option "0" depicting no sexual stimulation/intercourse, the scores are summed.
Time Frame
Baseline, week 6, and week 14

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients aging from 18 to 75 years diagnosed with prostate cancer undergoing ADT; with an average of 3 or more hot flashes a day for at least 3 days before enrollment and no other clinically significant disease; not receiving any medications for hot flashes nor did they have a previous history of acupuncture treatment. Exclusion Criteria: hormonal treatment other than GnRH analogue daily treatment with psychotropic drugs newly started or changed alternative medications with possible effects on flushes uncontrolled hypertension or metabolic disease inability to move/lie on the side, and treatment with anticoagulants or pacemaker.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jiani Wu, M.D., Ph.D.
Phone
13426116653
Email
jiani_wu@aliyun.com
First Name & Middle Initial & Last Name or Official Title & Degree
Zongshi Qin, M.D.
Phone
17888808861
Email
arisq@hku.hk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jiani Wu, M.D., Ph.D.
Organizational Affiliation
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
West China Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianqin Lv, MD
First Name & Middle Initial & Last Name & Degree
Jianqin Lv, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The deidentified participant data will be shared after publication. Researchers can access the data with a specific purpose and a signed data access agreement.
IPD Sharing Time Frame
With publication
IPD Sharing Access Criteria
For a specified purpose with a signed data access agreement

Learn more about this trial

Acupuncture Versus Sham Acupuncture or Usual Care for Antiandrogen-Induced Hot fLashes in Prostate Cancer (AVAIL)

We'll reach out to this number within 24 hrs